Sun Pharma, Lupin, Dr Reddys recall products in US market
As per the latest Enforcement Report of US Food and Drug Administration , the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US.
Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules due to "Failed Dissolution Specifications", the US health regulator stated.
The medication is used to treat attention deficit hyperactivity disorder .
The drug firm initiated the Class II recall in the US on June 16 this year, it added.
Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure.
Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets . The affected lot was manufactured at the company's Nagpur-based manufacturing facility.
As per the USFDA, the company initiated the Class II recall on June 20 due to "Product Mix Up".
This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg, the US health regulator stated.
In another filing, the US health regulator said that Dr Reddy's Laboratories is recalling 1,476 bottles of Omeprazole Delayed-release capsules.
The medication is used to treat certain stomach and esophagus problems.
Princeton-based Dr. Reddy's Laboratories, Inc initiated the Class II recall on June 30, 2025, USFDA stated.
The affected lot was produced at the company's Bachupally -based manufacturing facility.
The recall is due to the presence of foreign tablets/capsules, USFDA said.
It is due to the presence of foreign Divalproex Sodium extended-release 250mg tablets in a bottle of omeprazole capsules, it added.
As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
11 minutes ago
- New Indian Express
UP Man alleges 'towel-size' medical gauze found inside wife's body weeks after cesarean delivery
The pathology lab conducted the ultrasound test and then asked for an X-ray test, and subsequently a scan. "I gradually started feeling afraid and thought, why is the matter escalating?" he said. Kataria's fears worsened seeing the urgency with which the pathology lab carried out the CT-scan. He said an existing patient's test was stopped midway and his wife's CT-scan was conducted. He further said that when he asked the pathology lab to give him the reports, they refused and told him to first consult the gynaecologist, Sirohi. "When I reached the doctor's clinic, she was adamant about conducting a surgery. When I said that your nursing home is not equipped to conduct surgery, she said that she will remove the pus-like material using a syringe," he said. Kataria said he wanted a second opinion but Sirohi allegedly said there was no need for it and that his wife was "like a sister". Kataria also claimed that the pathologist tried every trick in the book to not give the report to him and relented only when he threatened to involve the police. He then took the appointment of another Ghaziabad-based doctor but claimed that by the time he reached her clinic, Sirohi had already called her "to not entertain" him. "My fears intensified. I asked the second doctor whether my wife needs to be admitted. She said that my wife must be admitted that very night itself, and there was no guarantee (of her being alive) the next day," Kataria said. "I realised that I have to admit my wife to a hospital in Delhi, and on the night of July 10, I took my wife and admitted her to a hospital in Patparganj (Delhi). Here, all tests were conducted on the night of July 10 itself. They could clearly see a foreign body in the tests," he said. Kataria said a surgery was planned for the next day (July 11). "After the surgery, which lasted for around 3 hours, a medical gauze, the size of a towel, was retrieved from inside my wife's body. Since that piece of cloth was inside her body for one-and-a-half months, it was attached to the ovary and other parts of the body," he claimed. Khurana was finally discharged on July 14, he said. Kataria said he has been getting calls from people saying that the Sirohis are influential people, and they dissuaded him from fighting them as it would be a long battle. "On July 16, I lodged a complaint with the chief medical officer. On July 17, I lodged a police complaint. Initially, the CMO assured me that he will take action against the doctor, but later he backtracked. A DCP-ranked officer, after five days, also said that an FIR be registered in the case, and issued instructions to the police station. When the copy of the complaint reached the CMO, he alleged "the CMO made a U-turn", saying his wife has not died while others have lost their wives and that their complaints are still pending for the past six months. "The CMO said that he wants to give one chance to the doctor (Sirohi)," Kataria said. When contacted, Ghaziabad Chief Medical Officer Dr Akhilesh Mohan on Monday told PTI, "A three-member team, which includes a gynaecologist, has been constituted to probe the matter. I have written a letter to the nursing home, where the treatment (cesarean delivery) was done. As soon as I get the letter, action will be taken." Dr Nishi Sirohi said she has received a letter from the CMO on the matter 3-4 days ago and that she has given her reply. "I feel that the person (Chirag Kataria) is speaking baseless things. The patient went from here in a proper condition. And (later), I told her that there is some pus in her stomach, and she should be admitted, so that treatment can be done after carrying out tests," she told PTI. "They did not come to me. And, now after one and a half months, I am getting this letter from the CMO. I will fully cooperate in the probe," she added.
The Wire
11 minutes ago
- The Wire
'Not a Side Effect of War': Israeli Human Rights Groups Say Israel Committing Genocide in Gaza
New Delhi: In a first, Tel Aviv-based human rights organisations, B'Tsalem and Physicians for Human Rights Israel, have released statements calling out Israel for committing the genocide of Palestinians in Gaza. They have said that Israel has systematically and deliberately targeted Palestinians and that its western allies have the power to stop it. In both their statements, the leading human rights groups have noted that Israel's policy towards Palestinians shifted on October 13, 2023, which marked the beginning of a military onslaught lasting more than 21 months and counting. B'Tsalem stated that it has resulted in mass killing, both directly and through creating unlivable conditions, serious bodily or mental harm to an entire population, decimation of basic infrastructure throughout the Gaza Strip, and forcible displacement on a huge scale, with ethnic cleansing added to the list of official war objectives. "The mass arrests and abuse of Palestinians in Israeli prisons, which have effectively become torture camps, and tearing apart the social fabric of Gaza, including the destruction of Palestinian educational and cultural institutions, compound it. The campaign is also an assault on Palestinian identity itself, through the deliberate destruction of refugee camps and attempts to undermine the United Nations Relief and Works Agency for Palestine Refugees (UNRWA)," it stated. The group also highlighted the failure of the international community in stopping the atrocities, especially the leaders of the Western world, particularly the United States and Europe, who, it said, "share responsibility by providing support that enables Israel's acts of destruction". Meanwhile, Physicians for Human Rights' statement focused on the starvation and killing of children by the Israeli occupation. "Each day, dozens die of malnutrition. Ninety-two percent of infants aged six months to two years don't get enough to eat. At least 85 children have already starved to death. Israel has displaced 9 in 10 Gazans, destroyed or damaged 92% of homes, and left over half a million children without schools or stability. It has wiped out essential health services – including dialysis, maternal care, cancer treatment, and diabetes management," it stated. The organisation said that this was not temporary but a "strategy to eliminate the conditions needed for life". "Even if Israel stops the offensive today, the destruction it has inflicted guarantees that preventable deaths – from starvation, infection, and chronic illness – will continue for years. This is not collateral damage. This is not a side effect of war. It is the systematic creation of unlivable conditions. It is the denial of survivability. It is a genocide," it stated. B'Tsalem further warned that this genocide will not remain confined to the Gaza Strip, and that the actions and underlying mindset driving it may be extended to other areas as well. "The recognition that the Israeli regime is committing genocide in the Gaza Strip, and the deep concern that it may expand to other areas where Palestinians live under Israeli rule, demand urgent and unequivocal action from both Israeli society and the international community," it said. The groups have urged international community to fulfil its duty Ito stop the genocide Israel is carrying out in Gaza. The death toll in Gaza now stands close to 60,000, as per the health ministry data, and the remaining population is on the verge of famine. Over the weekend, Israel announced a few measures to allow aid access, including a limited 10-hour daily "tactical pause" in certain areas of Gaza City. However, there have also been reports Israeli attacks taking place where people were trying to collect aid.
Mint
6 hours ago
- Mint
Indian contract drug makers timed their IPOs right. But is the business worth the premium?
An anticipated shift in the global pharmaceutical supply chain away from China has investors excited about Indian contract research, development and manufacturing organisations (CRDMOs), companies that offer services from early-stage drug discovery to late-stage drug development. Export-focused CRDMOs including Anthem Biosciences, Sai Life Sciences and Divi's Laboratories are trading at expensive valuations, reflecting investor enthusiasm as innovator drug companies look at diversifying and derisking their operations. However, experts cautioned that while CRDMOs are expected to post high growth, their financial performances have yet to reflect it. Bengaluru-based Anthem Biosciences made a stellar debut on the stock exchanges on 21 July, listing on the National Stock Exchange at a premium of 27 percent over its initial public offering price of ₹ 570. The IPO, with an issue size of ₹ 3,395.79 crore, was subscribed 67.42 times. Anthem's stock traded at a price-to-earnings (PE) ratio of 93.24 on 25 July. 'The good news is that… China is a behemoth. So, we have that much headroom to grow,' Ajay Bhardwaj, managing director and chief executive officer, told Mint earlier. About 65% of India's imported bulk drugs and advanced drug intermediates worth $3.5 billion in FY25 came from China, according to the commerce ministry. The government wants to strengthen local manufacturing through an upgraded drugs production-linked incentive scheme as it pushes for self-sufficiency in bulk drugs that go into manufacturing medicines. The Indian CRDMO industry today is worth $3-3.5 billion, making up only 2-3% of the global CRDMO market, which is worth $145 billion. It grew at a compound annual growth rate of 15% from 2019-2024, according to a recent report by BCG and IPSO. The industry is at a tipping point, with strong fundamentals and massive headroom to grow, fueled by competitive advantage in small molecule capabilities, faster startup time, focus on quality and cost advantages, the report noted. Unlike CRDMOs, CDMOs (contract development and manufacturing organisations) are typically involved in manufacturing already commercialised drugs. Sai Life Sciences, which made its market debut in December 2024, traded at ₹ 837 on 25 July, close to its high of about ₹ 851, valuing the company at roughly 102 times trailing earnings and about 8.2 times book value. Divi's Laboratories and Syngene International also traded at premiums, at a PE ratio of 80.31 and 55.09, respectively. In comparison, generic pharmaceutical giants are valued relatively modestly: Sun Pharmaceutical Industries trades at a PE ratio of 37.37, Dr Reddy's Laboratories at 18.84, and Cipla at 23.53. Sai Life Sciences shares are up over 18% since listing on the NSE. Divi's Laboratories gained 35.56% from 30 July 2024 to 28 July 2025, Piramal Pharma rose 20.36%, while Syngene International's shares were down 12.72%. Syngene International, a unit of biopharmaceutical company Biocon, kicked off this fiscal's earnings season last week. It posted an 11% year-on-year rise in revenue from operations to ₹ 875 crore for Q1, a robust start compared to its FY25 performance (4% revenue growth YoY). The management maintained its expectation of revenue growth in the mid‑teens for FY26. Sai Life Sciences delivered 16% revenue growth to ₹ 1,695 crore in FY25. Divi's reported a 19% year-on-year rise in full-year revenue to ₹ 9,360 crore in FY25, while net profit surged 37% to ₹ 2,191 crore. Divi's is expected to post revenue growth of 18% year-on-year in Q1FY26, according to brokerage BNP Paribas. 'The Indian CDMO sub-sector presents a highly promising opportunity as investors view it as a direct beneficiary of the China+1 thematic,' Sunil Khaitan, managing director leading financing in India at Goldman Sachs, told Mint. 'We expect the capital markets activity in this space to further accelerate over the next 6-12 months.' The China-plus one theme – to diversify supply chains and reduce overdependence on China – is a key driver, but it's not just that. CRDMOs are on an aggressive capacity expansion track as they anticipate winning over more clients in the future and bank on technological niches to cater to biotech companies as demand for new technologies and drugs grows. Anthem has expertise in new chemical entities as well as biologics (drugs made from living organisms or their components) and capabilities to work on RNAi (a gene regulatory mechanism), antibody drug conjugates that target and kill cancer cells, peptides (short chains of amino acids), lipids, and oligonucleotides (synthesised nucleic acids). OneSource Specialty Pharma, a subsidiary of Strides Pharma, which listed in January, expects its focus on niche areas such as biologics, drug substances, injectables, and drug-device combinations to drive growth. Its offerings in drug-device combinations, particularly for GLP-1s (hormones that regulate blood sugar levels), which are often sold in pen-filled devices, is expected to be a major growth opportunity. 'We are currently executing a 5x expansion of our cartridge-filling capabilities to meet our customer demand and which will significantly boost future revenue,' CEO Neeraj Sharma told Mint in an emailed response. Anthem Biosciences and Sai Life Sciences did not respond to Mint's queries. Investors are looking at CRDMOs not just for potential growth driven by these tailwinds but also as diversification of their portfolios, experts said. Opportunities in traditional pharma companies with a focus on domestic formulations and US generics are drying up because of a slowdown in new approvals and regulatory issues. 'The investor would like to have exposure to companies and segments which have the potential for high growth and themes of shifting manufacturing from China to India,' Tausif Shaikh, healthcare and pharma analyst at BNP Paribas, told Mint. While CRDMOs have reported steady, mid-teen revenue growth, their performance has not been encouraging enough even as valuations remain expensive, Shaikh pointed out. Unlike sectors such as healthcare services, where one can gauge a company's performance based on metrics like hospital bed occupancy and average revenue per bed, for contract drug manufacturers, management commentary is the main indicator of the company's expected growth and performance, said Shaikh. Most companies report an uptick in interest from innovators to hire their services and have embarked on aggressive capacity expansion. Syngene plans to boost its biologics manufacturing footprint in FY26 through its newly acquired US facility for $36.5 million. Divi's Laboratories is undertaking a ₹ 650-700 crore capacity expansion at its existing facilities, while Sai Life Sciences has completed the second phase of its Bidar Unit IV capacity expansion for small-molecule active pharmaceutical ingredients and intermediates. On the back of this, the growth outlook remains strong. "Earnings are expected to be strong for export-oriented CDMOs for the next 2-3 years considering the capex projects and potential addition of new molecules,' Shrikant Akolkar, pharma equity research analyst at brokerage Nuvama, told Mint. However, the CDMO business is non-linear, Akolkar said, adding that one must pay attention to the annual performance and not a couple of quarters of number misses.
